EDMONTON, AB, Jan. 3, 2024 /CNW/ - Imperial Equities Inc. (TSXV: IEI), through its Board of Directors, has declared a quarterly dividend of $0.02 per share effective Q1 2024, payable on February 5, 2024 to shareholders of record effective January 19, 2024.
"As we begin 2024, our Company's performance and optimism for the future remain strong," said Sine Chadi, President and CEO of Imperial Equities. "We are pleased to issue a dividend again this Quarter in recognition and appreciation of our shareholders' continued support, confidence and trust."
This dividend is an eligible dividend for the purposes of the Income Tax Act.
About Imperial Equities Inc:
Based in Edmonton, Alberta, Imperial Equities Inc. is a publicly traded company anchored by industrial, agricultural, and commercial real estate properties in its targeted markets throughout Western Canada. Additional information is available at: www.imperialequities.com. Imperial's common shares are listed on the TSX Venture Exchange under symbol IEI.
Neither TSX Venture nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
In line with their commitment to upholding the highest standards of transparency, below is the Adani Portfolio's Credit and Result compendium for financial year 2023-24.
The performance in FY24 and the past five years signify the strength and...
Linker Vision, a pioneer in AI technology, is proud to announce a collaboration with NVIDIA aimed at accelerating vision AI adoption across enterprise applications with large vision models (LVMs). Through this collaboration, Linker Vision is poised...
ConcertAI, the leading oncology real-world evidence data and AI SaaS technology company, today announced a collaboration with NVIDIA to advance a broad set of translational and clinical development solutions within the ConcertAI CARA AI platform....
Vention, the company behind the cloud-based Manufacturing Automation Platform (MAP), today announced a collaboration with NVIDIA to bring industrial automation technology to small and medium manufacturers by using NVIDIA AI and accelerated computing...
Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C inhibitor glecirasib (JAB-21822) in combination with a SHP2 inhibitor (JAB-3312) in frontline non-small cell lung...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...
